Shanghai Pharmaceuticals has issued a clarification on media reports about its acquisition of Cardinal Health’s pharmaceutical distribution business in China.

The firm informed that the submission of first and second rounds of bids for the potential acquisition of Cardinal China occurred on 21 July and 15 September of this year, respectively.

Shanghai further noted that the second round is still at the non-exclusive bidding stage and has uncertainties.

Details of the bidding process and terms such as bidding price, Cardinal China’s operational and financial conditions have not been divulged due to confidentiality requirements.

Cardinal China business comprises national drugs and medical devices distribution, hospital direct sales, special drugs, specialist pharmacies and commercial technology segments.

“Cardinal China business comprises national drugs and medical devices distribution, hospital direct sales, special drugs, specialist pharmacies and commercial technology segments.”

The company’s distribution network, which caters to 322 cities and around 11, 000 medical organisations, includes 14 hospital direct sales firms, 17 distribution centres and 30 DTP pharmacies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Last year, Cardinal’s main business income in the country was reported to be approximately CNY25.4bn ($3.83bn).

The acquisition is in line with Shanghai’s strategic goal to expand distribution, accelerate national layout and improve service contents.

Shanghai expects that upon completion, the transaction would bolster its footprint in pharmaceutical distribution industry of China, including import products agency, professional third-party pharmaceutical logistics, DTP pharmacies and distribution of medical devices.

In addition to the assessment of Cardinal China’s business development in the future, the acquisition proposals are subject to further negotiations between the parties following the selection and acceptance of relevant submissions from the bidders.